Innate Pharma SA
PAR:IPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Innate Pharma SA
PAR:IPH
|
FR |
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
CA |
Wall Street
Price Targets
IPH Price Targets Summary
Innate Pharma SA
According to Wall Street analysts, the average 1-year price target for
IPH
is 6.273 EUR
with a low forecast of 6.161 EUR and a high forecast of 6.51 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is IPH's stock price target?
Price Target
6.273
EUR
According to Wall Street analysts, the average 1-year price target for
IPH
is 6.273 EUR
with a low forecast of 6.161 EUR and a high forecast of 6.51 EUR.
What is Innate Pharma SA's Revenue forecast?
Projected CAGR
175%
For the last 14 years the
compound annual growth rate for
Innate Pharma SA's revenue is
-7%.
The projected
CAGR
for the next 3 years is
175%.
